WO1999029686A1 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
WO1999029686A1
WO1999029686A1 PCT/SE1998/002190 SE9802190W WO9929686A1 WO 1999029686 A1 WO1999029686 A1 WO 1999029686A1 SE 9802190 W SE9802190 W SE 9802190W WO 9929686 A1 WO9929686 A1 WO 9929686A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridyl
yloxy
butyl
dione
group
Prior art date
Application number
PCT/SE1998/002190
Other languages
English (en)
Inventor
Andrew Baxter
David Cheshire
Thomas Mcinally
Michael Mortimore
David Cladingboel
Original Assignee
Astrazeneca Uk Limited
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited, Astrazeneca Ab filed Critical Astrazeneca Uk Limited
Priority to KR1020007006117A priority Critical patent/KR20010032800A/ko
Priority to SK844-2000A priority patent/SK8442000A3/sk
Priority to JP2000524280A priority patent/JP2001525406A/ja
Priority to EEP200000321A priority patent/EE200000321A/xx
Priority to EP98962753A priority patent/EP1037889A1/fr
Priority to AU17915/99A priority patent/AU1791599A/en
Priority to CA002312357A priority patent/CA2312357A1/fr
Priority to IL13636898A priority patent/IL136368A0/xx
Priority to BR9813378-0A priority patent/BR9813378A/pt
Publication of WO1999029686A1 publication Critical patent/WO1999029686A1/fr
Priority to NO20002787A priority patent/NO20002787L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel compounds, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
  • the P2X ⁇ receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflamjmatory/ixnmune process, specifically, macrophages, mast cells and lymphocytes (T and B).
  • P2X ⁇ receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells) and hepatocytes.
  • P2X receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X ⁇ receptor may play a role.
  • X represents an oxygen or sulphur atom or a group NH, CH2, CH2CH2 or OCH2;
  • R represents a pyridyl (especially 3-pyridyl or 4-pyridyl) orpyrimidinyl group;
  • R represents a phenyl, pyridyl or pyrimidinyl group, each of which may be optionally substituted by one or more substituents independently selected from a halogen atom or an amino, cyano, hydroxyl, nitro, Ci-C ⁇ -alkyl, halo-Cj-Cg-alkyl, Cj-Cg-alkoxy,
  • R 3 and R 4 each independently represent a hydrogen atom or a Q-Cg-alkyl group
  • R and R each independently represent a hydrogen atom or a Q-Cg-alkyl group, or together with the nitrogen atom to which they are attached form apyrrolidinyl or piperidinyl group; or a pharmaceutically acceptable salt or solvate thereof.
  • an alkyl substituent or alkyl moiety in a substituent group may be linear or branched and also the alkyl moieties in a dialkylamino substituent group may be the same or different.
  • X represents a group OCH 2
  • the oxygen atom is positioned adjacent the carbonyl group in the ring.
  • the group R preferably represents a phenyl, pyridyl or pyrimidinyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from a halogen atom (e.g. fluorine, chlorine, bromine or iodine) or an amino, cyano, hydroxyl, nitro, Ci-Cg-alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), halo-Ci-C ⁇ -alkyl (e.g. trifluoromethyl), -Cg-alkoxy (e.g.
  • a halogen atom e.g. fluorine, chlorine, bromine or iodine
  • an amino, cyano, hydroxyl, nitro Ci-Cg-alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl
  • Ci-C ⁇ -alkylthio e.g. methyl-, ethyl-, propyl-, butyl-, pentyl- or hexylthio
  • Ci-C ⁇ -C6-alkylamino e.g. methylamino, dimethylamino, ethylamino or diethylamino
  • Ci-Cg-alkylcarbonyl e.g. methyl-, ethyl-, propyl-, butyl-,pentyl- or hexylcarbonyl
  • -C ⁇ -alkoxycarbonyl e.g.
  • Ci-Cg-alkylsulphinyl e.g. methyl-, ethyl-, propyl-, butyl-, pentyl- or hexylsulphinyl
  • Ci-Cg-alkylsulphonyl e.g.
  • -NR SO2R or -SO2NR R group or a group -Z-(CH2)p-Z-(CH2)q-H wherein each Z independently represents a nitrogen or oxygen atom, p is an integer from 2 to 5 and q is 0 or an integer from 1 to 5.
  • R represents a phenyl, pyridyl or pyrimidinyl group, each of which may be optionally substituted by one, two or three substituents independently selected from a halogen atom or an amino, cyano, hydroxyl, nitro, C ⁇ -C 4 -alkyl, halo-C ⁇ -C 4 -alkyl,
  • R represents a phenyl, pyridyl or pyrimidinyl group, each of which may be optionally substituted by one or two substituents independently selected from a halogen atom or an amino, cyano, nitro, C ⁇ -C4-alkyl, halo-C ⁇ -C4-alkyl,
  • R represents a phenyl or pyridyl group optionally substituted by one or two substituents independently selected from a fluorine or chlorine atom or an amino, cyano, nitro, trifluoromethyl, methoxy or -SO2NR R group.
  • R and R each independently represent a hydrogen atom or a
  • C ⁇ -C4-alkyl group e.g. methyl or ethyl group.
  • R and R each independently represent a hydrogen atom or a
  • C ⁇ -C4-alkyl group e.g. methyl or ethyl group
  • Preferred compounds of the invention include:
  • (+/-)-N- [ 1 -(3 ' - ⁇ itrobiphenyl-4-yloxy)-4-(4-pyridyl)-2-butyl]-imidazolidine-2,4-dione, (+/-)-N-[l-(3'-Nitrobiphenyl-4-yloxy)-4-(4-pyridyl)-2-butyl]-piperidin-2-one, and (+/-)-N- [ 1 -(3 ' - ⁇ itrobiphenyl-4-yloxy)-4-(4-pyridyl)-2-butyl]-pyrrolidin-2-one.
  • the present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises: (a) reacting a compound of general formula
  • L represents a leaving group (e.g. a hydroxyl group) and R 1 and R 2 are as
  • X and Y are as hereinbefore defined except that when X is an oxygen atom or OCH 2 group, then Y is not a CH 2 group; or
  • X represents an oxygen atom or OCH 2 group and Y and R 1 are as hereinbefore defined, with a compound of general formula (VI), R 2 -B(OH) 2 , wherein R 2 is as hereinbefore defined; or
  • X represents an oxygen atom or OCH 2 group and Y and R 1 are as hereinbefore defined, with a compound of general formula (VHI), R ⁇ -Br, wherein R 2 is as hereinbefore defined; and optionally after (a), (b), (c), (d), (e), (f) or (g) converting the compound of formula (I) to a further compound of formula (I) and/or forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).
  • VHI general formula
  • R ⁇ -Br wherein R 2 is as hereinbefore defined
  • the processes (a), (b), (c), (d), (e), (f) and (g) may conveniently be carried out in a solvent (e.g. dichloromethane, chloroform, acetonitrile, dioxan or tetrahydrofuran), at a temperature in the range from 0 to 100 °C, preferably in the range from 10 to 80 °C, and especially at ambient temperature (20 °C).
  • a solvent e.g. dichloromethane, chloroform, acetonitrile, dioxan or tetrahydrofuran
  • the compounds of formula (II) are known from WO 97/20815 and WO 98/42670 or may be prepared by processes analogous to those described in WO 97/20815 and
  • the compounds of formula (UI), (VI) and (VD3) are known or commercially available compounds, or may be prepared by processes known in the art.
  • the compounds of formula (IV) may be prepared by methods known in the art starting from the compounds of formula (II).
  • the compounds of formula (V) and (VII) may be prepared by processes analogous to (a), (b) or (c) above using the corresponding bromo- or boron-containing compound of formula (II) or (IN).
  • nitrophenyl group can be converted to compounds of formula (I) where R is an aminophenyl group by reduction using iron powder and ammonium chloride in ethanol or an ethanol water mixture under reflux conditions.
  • the compounds of formula (I) above may be converted to a pharmaceutically- acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate orp-toluenesulphonate, or an alkali metal salt such as a sodium or potassium salt.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
  • the compounds of the present invention are advantageous in that they possess pharmacological activity. They are therefore indicated as pharmaceuticals for use in the treatment or prevention of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, hyperresponsiveness of the airway, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myocardial ischaemia, cardiac reperfusion damage, cerebral ischaemia, stroke, myoblastic leukaemia, diabetes, Alzheimer's disease, osteoporosis, burn injury, stroke, varicose veins and meningitis.
  • the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • the invention provides the use of a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • the invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis or psoriasis) which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined to a patient.
  • a method of effecting immunosuppression e.g. in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis or psoriasis
  • the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
  • the compounds of formula (I) and pharmaceutically-acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically-acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined in association with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition of the invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
  • topically e.g. to the lung and/or airways or to the skin
  • solutions e.g. to the lung and/or airways or to the skin
  • systemically e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
  • MS mass spectrometry
  • nuclear magnetic resonance nuclear magnetic resonance
  • dimethylsulphoxide
  • Boiling point 140 °C (oil pump) MS (gems) 228/230 M +
  • Example 6c Prepared according to the method of Example 6c) using l-(4-bromophenyloxy)-4- (4-pyridyl)-2-butanol (0.40 g) prepared as described in Example 6b) and 4-fluorophenylboronic acid (0.28 g), to deliver the sub-title compound as a colourless solid (0.23 g).
  • (+/-)-N-[l-(Biphenyl-4-yloxy)-4-(3-pyridyl)-2-butyl]-isoindole-l ,3-dione (3.41 g) was dissolved in a solution of 30 % methylamine in methanol (100 ml). The solution was heated to reflux temperature for 3 hours. The solvent was removed under reduced pressure, the residue dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, filtered and concentrated. Purification by chromatography over neutral alumina, eluting with 10% methanol in dichloromethane gave the sub-title compound as a cream solid (1.08g).
  • Example 40a Prepared according to the method of Example 1 with (2R)-l-(4-bromophenoxy)-4-(3- pyridyl)-2-butanol (0.214 g) as prepared in Example 40a) of WO 97/20815 and 3-chloro- 4-fluorophenylboronic acid (0.18 g), yielding the sub-title compound as a yellow gum (0.24 g).
  • the reaction mixture was partitioned between diethyl ether and 2N hydrochloric acid and the layers separated.
  • the aqueous phase was neutralised with 2N sodium hydroxide and extracted with ethyl acetate.
  • the organic phase was separated, dried over anhydrous magnesium sulphate, filtered and concentrated under reduced pressure to give a residue.
  • the residue was dissolved in tetrahydrofuran (25ml) and tetrabutylammonium fluoride (0.163 g) was added. After stirring at room temperature overnight the mixture was concentrated under reduced pressure and partitioned between diethyl ether and 2N hydrochloric acid. The layers were separated.
  • Example 6c Prepared according to the method of Example 6c) using l-(4-bromophenoxy)-4-(4- pyridyl)-2-butanol (0.20 g) prepared as described in Example 6b) and 3-trifluoromethylphenylboronic acid (0.13 g), to deliver the sub-title compound as a yellow oil (0.18 g).
  • (+/-)-N-[l-(3'-(Trifluoromethyl)biphenyl-4-yloxy)-4-(4-pyridyl)-2-butyl]- thiazo!idin-2,4-dione Prepared according to the method of Example 1 with (+/-)- 1 -(3' - trifluoromethylbiphenyl-4-yloxy)-4-(4-pyridyl)-2-butanol (0.175g), from step a) and 2,4-thiazolinedione (0.106 g).
  • Example 6c Prepared according to the method of Example 6c) using l-(4-bromophenoxy)-4-(4- pyridyl)-2-butanol (0.20 g) prepared as described in Example 6b) and
  • Example 32a Prepared according to the method described in Example 6c) using (+/-)-N-[l-(4- bromophenoxy)-4-(4-pyridyl)-2-butyl]-oxazolidin-2-one (Example 32a), O.lOOg), phenylboronic acid (0.047 g), ethanol (3 ml), aqueous sodium bicarbonate solution (2M, 0.2 ml) and tetrakis-(triphenylphosphine)palladium(0) (0.010 g).
  • Example 32a (+/-)-N-[l-(4- bromophenoxy)-4-(4-pyridyl)-2-butyl]-oxazolidin-2-one (Example 32a), O.lOOg), 4-chlorobenzeneboronic acid (0.060 g), ethanol (3 ml), aqueous sodium bicarbonate solution (2M, 0.2 ml) and tetrakis-(triphenylphosphine)palladium(0) (0.010 g).
  • Example 32a Prepared according to the method described in Example 6c) using (+/-)-N-[l-(4- bromophenoxy)-4-(4-pyridyl)-2-butyl]-oxazolidin-2-one (Example 32a), O.lOOg), 4-methylbenzeneboronic acid (0.052 g), ethanol (3 ml), aqueous sodium bicarbonate solution (2M, 0.2 ml) and tetrakis-(triphenylphosphine)palladium(0) (0.010 g).
  • Example 32a (+/-)-N-[l-(4- bromophenoxy)-4-(4-pyridyl)-2-butyl]-oxazolidin-2-one (Example 32a), O.lOOg), 4- methoxybenzeneboronic acid (0.059 g), ethanol (3 ml), aqueous sodium bicarbonate solution (2M, 0.2 ml) and tetrakis-(triphenylphosphine)palladium(0) (0.010 g). After work-up, the residue was purified by NPHPLC eluting a gradient of 0-10% ethanol in dichloromethane to give the title compound as a solid (0.026 g).
  • Example 32b ((+/-)-[4-(4- Pyridyl)-2-(oxazolidin-2-one-l-yl)butoxy]benzeneboronic acid (Example 32b), 0.050 g), 1- bromo-3,4-dichlorobenzene (0.048 g), ethanol (2 ml), aqueous sodium bicarbonate solution (2M, 0.1 ml) and tetrakis-(triphenylphosphine)palladium(0) (0.006 g).
  • (+/-)-l-(4-Bromophenoxy)-4-(4-pyridyl)-2-(te/ -butyldimethylsilyloxy)butane tert-Butyldimethylsilyl chloride (20.53 g) andimidazole (9.25 g) were added to a solution of (+/-)- l-(4-bromophenyloxy)-4-(4-pyridyl)-2-butanol (Example 6b), 14.60g) in dry dichloromethane (500 ml). The solution was stirred overnight at room temperature.
  • (+/-)-4-[4-(4-Pyridyl)-2-(fert-butyldimethylsayloxy)butoxy]benzeneboronic acid Prepared according to the method described in Example 18b) using (+/-)- 1 -(4- bromophenoxy)-4-(4-pyridyl)-2-(tert-butyldimethylsilyloxy)butane (lO.Og), from step a), tert-butyllithium (1.7 M solution in hexanes, 27 ml) and tri-wopropylborate (6 ml) in dry tetrahydrofuran (200 ml).
  • (+/-)-l-[4-(6-Methoxypyridin-2-yl)phenoxy]-4-(4-pyridyl)-2-butanoI Prepared according to the method described in Example 6c) using (+/-)-4-[4-(4- pyridyl)-2-butoxy]benzeneboronic acid (0.20 g) from step c), 2-bromo-6-methoxypyridine (J. Org. Chem., 55, (1990), 69-73, 0.26 g), ethanol (3 ml), aqueous sodium bicarbonate solution (2M, 0.7 ml) and tetrakis-(triphenylphosphine)palladium(0) (0.020 g).
  • Example 15a Prepared according to the method of Example 1 using (+/-)-N-l-(3'-nitrobiphenyl-4- yloxy)-4-(4-pyridyl)-2-butanol (Example 15a), 0.20 g), hydantoin (0.11 g), triphenylphosphine (0.29 g) and diethyl azodicarboxylate (0.17 ml) in dry tetrahydrofuran (10 ml) and dimethylformamide (2 ml).
  • bbATP a P2X receptor agonist
  • pyridoxal 5-phosphate a P2X ⁇ receptor antagonist

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne de nouveaux composés, leur procédé de préparation, des compositions pharmaceutiques les contenant, un procédé de préparation de ces compositions pharmaceutiques et leur utilisation en thérapie.
PCT/SE1998/002190 1997-12-05 1998-12-01 Nouveaux composes WO1999029686A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020007006117A KR20010032800A (ko) 1997-12-05 1998-12-01 신규 화합물
SK844-2000A SK8442000A3 (en) 1997-12-05 1998-12-01 Hetorocyclic compounds, method for the preparation thereof, pharmaceutical composition comprising the same and their use
JP2000524280A JP2001525406A (ja) 1997-12-05 1998-12-01 新規な化合物
EEP200000321A EE200000321A (et) 1997-12-05 1998-12-01 Uudsed ühendid
EP98962753A EP1037889A1 (fr) 1997-12-05 1998-12-01 Nouveaux composes
AU17915/99A AU1791599A (en) 1997-12-05 1998-12-01 Novel compounds
CA002312357A CA2312357A1 (fr) 1997-12-05 1998-12-01 Nouveaux composes
IL13636898A IL136368A0 (en) 1997-12-05 1998-12-01 Novel compounds
BR9813378-0A BR9813378A (pt) 1997-12-05 1998-12-01 Composto, processo para preparar o mesmo, e uso do mesmo, composição farmacêutica, e processo para a preparação da mesma, e, processo de efetuar a imunossupressão
NO20002787A NO20002787L (no) 1997-12-05 2000-05-31 Nye forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704546-2 1997-12-05
SE9704546A SE9704546D0 (sv) 1997-12-05 1997-12-05 Novel compounds

Publications (1)

Publication Number Publication Date
WO1999029686A1 true WO1999029686A1 (fr) 1999-06-17

Family

ID=20409283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/002190 WO1999029686A1 (fr) 1997-12-05 1998-12-01 Nouveaux composes

Country Status (16)

Country Link
EP (1) EP1037889A1 (fr)
JP (1) JP2001525406A (fr)
KR (1) KR20010032800A (fr)
CN (1) CN1284074A (fr)
AU (1) AU1791599A (fr)
BR (1) BR9813378A (fr)
CA (1) CA2312357A1 (fr)
EE (1) EE200000321A (fr)
HU (1) HUP0100731A3 (fr)
IL (1) IL136368A0 (fr)
NO (1) NO20002787L (fr)
PL (1) PL340837A1 (fr)
SE (1) SE9704546D0 (fr)
SK (1) SK8442000A3 (fr)
TR (1) TR200001544T2 (fr)
WO (1) WO1999029686A1 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071529A1 (fr) * 1999-05-25 2000-11-30 Astrazeneca Ab Composes phenyle substitues a activite immunosuppresseur et compositions pharmaceutiques
WO2001044213A1 (fr) * 1999-12-17 2001-06-21 Astrazeneca Ab Nouveaux antagonistes des recepteurs p2x7 utiles dans le traitement de maladies inflammatoires, immunitaires ou cardiovasculaires
GB2372564B (en) * 2000-10-21 2003-07-09 Astrazeneca Ab Chemical compounds
US6720452B2 (en) 1999-12-09 2004-04-13 Astrazeneca Ab Adamantane derivatives
WO2004058270A1 (fr) 2002-12-31 2004-07-15 Pfizer Products Inc. Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide utilises comme inhibiteurs de p2x7 pour le traitement de maladies inflammatoires
US6881754B2 (en) 1999-12-17 2005-04-19 Astrazeneca Ab Adamantane derivatives
US6927219B2 (en) 2001-11-12 2005-08-09 Pfizer Inc. N-alkyl-adamantyl triazinyl benzamide derivatives
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
US7186742B2 (en) 2003-05-12 2007-03-06 Pfizer Inc Benzamide inhibitors of the P2X7 receptor
US7214677B2 (en) 2001-11-12 2007-05-08 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
US7235657B2 (en) 2004-06-29 2007-06-26 Pfizer Inc. Methods for preparing P2X7 inhibitors
WO2007109192A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109160A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109172A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2008003697A1 (fr) * 2006-07-06 2008-01-10 Glaxo Group Limited N-phenylmethyl -5-oxo-proline-2-amides substitués tenant lieu d'antagonistes du récepteur p2x7 et procédés d'utilisation
US7326792B2 (en) 2003-07-21 2008-02-05 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
WO2008112205A1 (fr) 2007-03-09 2008-09-18 Renovis, Inc. Composés de bicyclohétéroaryle utilisés comme modulateurs de p2x7 et leurs utilisations
WO2008116845A1 (fr) * 2007-03-28 2008-10-02 Glaxo Group Limited Dérivés pipéridone carboxamide comme modulateurs du p2x7
WO2008119685A2 (fr) * 2007-03-29 2008-10-09 Glaxo Group Limited Dérivés d'oxazolidine et de morpholine carboxamide comme modulateurs de p2x7
WO2008119825A2 (fr) * 2007-04-03 2008-10-09 Glaxo Group Limited Dérivés imidazolidine carboxamide comme modulateurs de p2x7
EP2105164A1 (fr) 2008-03-25 2009-09-30 Affectis Pharmaceuticals AG Nouveaux antagonistes P2X7R et leur utilisation
WO2010118921A1 (fr) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2011054820A1 (fr) 2009-11-03 2011-05-12 Universidad Del País Vasco Procédé et compositions pour le traitement de l'ischémie de la matière blanche
US7956069B2 (en) 2006-06-09 2011-06-07 Astrazeneca Ab Compounds
EP2386541A1 (fr) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Nouveaux procédés de préparation d'antagonistes de P2X7R
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2012110190A1 (fr) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Nouveaux antagonistes p2x7r et leur utilisation
WO2012163456A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
US11324681B2 (en) 2017-12-20 2022-05-10 3M Innovative Properties Company Oral compositions and methods of use
US11779446B2 (en) 2017-11-21 2023-10-10 3M Innovative Properties Company Oral compositions and methods of use
US11801231B2 (en) 2017-12-20 2023-10-31 3M Innovative Properties Company Oral compositions and methods of use

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613473D0 (en) * 2006-07-06 2006-08-16 Glaxo Group Ltd Novel compounds
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071529A1 (fr) * 1999-05-25 2000-11-30 Astrazeneca Ab Composes phenyle substitues a activite immunosuppresseur et compositions pharmaceutiques
JP2003500399A (ja) * 1999-05-25 2003-01-07 アストラゼネカ・アクチエボラーグ 免疫抑制活性を有する置換フェニル化合物および医薬組成物
US6555541B1 (en) 1999-05-25 2003-04-29 Astrazeneca Uk Limited Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
US6720452B2 (en) 1999-12-09 2004-04-13 Astrazeneca Ab Adamantane derivatives
US7132457B2 (en) 1999-12-17 2006-11-07 Astrazeneca Ab Adamantane derivatives
CN1304382C (zh) * 1999-12-17 2007-03-14 阿斯特拉曾尼卡有限公司 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
US6812226B2 (en) 1999-12-17 2004-11-02 Astrazeneca Ab P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease
US6881754B2 (en) 1999-12-17 2005-04-19 Astrazeneca Ab Adamantane derivatives
WO2001044213A1 (fr) * 1999-12-17 2001-06-21 Astrazeneca Ab Nouveaux antagonistes des recepteurs p2x7 utiles dans le traitement de maladies inflammatoires, immunitaires ou cardiovasculaires
US7297818B2 (en) 1999-12-17 2007-11-20 Astrazeneca Ab Adamantane derivatives
GB2372564B (en) * 2000-10-21 2003-07-09 Astrazeneca Ab Chemical compounds
US7235549B2 (en) 2001-11-12 2007-06-26 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
US6927219B2 (en) 2001-11-12 2005-08-09 Pfizer Inc. N-alkyl-adamantyl triazinyl benzamide derivatives
US7214677B2 (en) 2001-11-12 2007-05-08 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
US7407956B2 (en) 2002-12-31 2008-08-05 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
US7176202B2 (en) 2002-12-31 2007-02-13 Pfizer Inc. Benzamide inhibitors of the P2X7 receptor
US6974812B2 (en) 2002-12-31 2005-12-13 Pfizer Inc. Benzamide inhibitors of the P2X7 Ereceptor
WO2004058270A1 (fr) 2002-12-31 2004-07-15 Pfizer Products Inc. Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide utilises comme inhibiteurs de p2x7 pour le traitement de maladies inflammatoires
US7186742B2 (en) 2003-05-12 2007-03-06 Pfizer Inc Benzamide inhibitors of the P2X7 receptor
US7553972B2 (en) 2003-05-12 2009-06-30 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
US7326792B2 (en) 2003-07-21 2008-02-05 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
US7741493B2 (en) 2003-07-21 2010-06-22 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
US7235657B2 (en) 2004-06-29 2007-06-26 Pfizer Inc. Methods for preparing P2X7 inhibitors
WO2007109160A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109172A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109192A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
US7956069B2 (en) 2006-06-09 2011-06-07 Astrazeneca Ab Compounds
US8048907B2 (en) 2006-07-06 2011-11-01 Glaxo Group Limited Receptor antagonists and their methods of use
US7718693B2 (en) 2006-07-06 2010-05-18 Glaxo Group Limited Receptor antagonists and their methods of use
AU2007271182B2 (en) * 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
EA016076B1 (ru) * 2006-07-06 2012-01-30 Глэксо Груп Лимитед Замещенные n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения
WO2008003697A1 (fr) * 2006-07-06 2008-01-10 Glaxo Group Limited N-phenylmethyl -5-oxo-proline-2-amides substitués tenant lieu d'antagonistes du récepteur p2x7 et procédés d'utilisation
WO2008112205A1 (fr) 2007-03-09 2008-09-18 Renovis, Inc. Composés de bicyclohétéroaryle utilisés comme modulateurs de p2x7 et leurs utilisations
WO2008116845A1 (fr) * 2007-03-28 2008-10-02 Glaxo Group Limited Dérivés pipéridone carboxamide comme modulateurs du p2x7
WO2008119685A2 (fr) * 2007-03-29 2008-10-09 Glaxo Group Limited Dérivés d'oxazolidine et de morpholine carboxamide comme modulateurs de p2x7
WO2008119685A3 (fr) * 2007-03-29 2008-11-20 Glaxo Group Ltd Dérivés d'oxazolidine et de morpholine carboxamide comme modulateurs de p2x7
US7932282B2 (en) 2007-04-03 2011-04-26 Glaxo Group Limited Imidazolidine carboxamide derivatives as P2X7 modulators
WO2008119825A2 (fr) * 2007-04-03 2008-10-09 Glaxo Group Limited Dérivés imidazolidine carboxamide comme modulateurs de p2x7
WO2008119825A3 (fr) * 2007-04-03 2008-12-11 Glaxo Group Ltd Dérivés imidazolidine carboxamide comme modulateurs de p2x7
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
EP2105164A1 (fr) 2008-03-25 2009-09-30 Affectis Pharmaceuticals AG Nouveaux antagonistes P2X7R et leur utilisation
WO2010118921A1 (fr) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2011054820A1 (fr) 2009-11-03 2011-05-12 Universidad Del País Vasco Procédé et compositions pour le traitement de l'ischémie de la matière blanche
WO2011141194A1 (fr) 2010-05-14 2011-11-17 Affectis Pharmaceuticals Ag Nouveaux procédés de préparation d'antagonistes du p2x7r
EP2386541A1 (fr) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Nouveaux procédés de préparation d'antagonistes de P2X7R
WO2012110190A1 (fr) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Nouveaux antagonistes p2x7r et leur utilisation
WO2012163456A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
US11779446B2 (en) 2017-11-21 2023-10-10 3M Innovative Properties Company Oral compositions and methods of use
US11324681B2 (en) 2017-12-20 2022-05-10 3M Innovative Properties Company Oral compositions and methods of use
US11801231B2 (en) 2017-12-20 2023-10-31 3M Innovative Properties Company Oral compositions and methods of use

Also Published As

Publication number Publication date
BR9813378A (pt) 2000-10-10
EP1037889A1 (fr) 2000-09-27
CA2312357A1 (fr) 1999-06-17
EE200000321A (et) 2001-08-15
HUP0100731A2 (hu) 2002-05-29
IL136368A0 (en) 2001-06-14
TR200001544T2 (tr) 2000-11-21
AU1791599A (en) 1999-06-28
KR20010032800A (ko) 2001-04-25
JP2001525406A (ja) 2001-12-11
SE9704546D0 (sv) 1997-12-05
PL340837A1 (en) 2001-02-26
HUP0100731A3 (en) 2002-08-28
NO20002787D0 (no) 2000-05-31
NO20002787L (no) 2000-08-01
CN1284074A (zh) 2001-02-14
SK8442000A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
EP1037889A1 (fr) Nouveaux composes
EP3661921B1 (fr) Inhibiteurs sélectifs de l'inflammasome nlrp3
US20230113085A1 (en) Novel small molecule inhibitors of tead transcription factors
AU2006207300B2 (en) Substituted triazole derivatives as oxytocin antagonists
EP1716135B1 (fr) Piperidinyl-carbonyl-pyrrolidines et leur utilisation en tant que agonistes de la melanocortine
EP3022202B1 (fr) Inhibiteurs de l'autotaxine comprennant un motif anneau hétéroaromatique-benzyle-amide-cycle
EP1352896B1 (fr) Dérivés d'adamantane pour le traitment de maladies inflammatoires, immunes et cardiovasculaire
US7649002B2 (en) (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
KR20160090304A (ko) 우레아 유도체 또는 그의 약리학적으로 허용되는 염
JP6356790B2 (ja) 新規ｃｙｐ１７阻害剤／抗アンドロゲン
KR20090110950A (ko) (피라진 유도체) 퀴녹살린 화합물 및 이의 용도
JP6746613B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
EP2974730A1 (fr) Médicaments pour maladies respiratoires
KR20210114972A (ko) 치환된 피롤리딘 아마이드 iii
JPH07145057A (ja) 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
JP2022534147A (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
DE69907845T2 (de) Sulfonamid-Derivate
MXPA00005327A (en) Novel compounds
KR20220016918A (ko) 오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법
WO2023177593A1 (fr) Inhibiteur phényle triazole pour l'interaction protéine-protéine mll1-wdr5
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
NZ786241A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
JPH0725854A (ja) 縮合ベンゼンオキシ酢酸誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136368

Country of ref document: IL

Ref document number: 98813490.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 09230464

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 17915/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998962753

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 504448

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000/01544

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2312357

Country of ref document: CA

Ref document number: 2312357

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/005327

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2000-2042

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 8442000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020007006117

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-2042

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998962753

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007006117

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998962753

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-2042

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007006117

Country of ref document: KR